DLD and Hepatic failure: Shany et al. compared the current mutation to the G229C mutation, which was reported in recurrent episodic liver failure, and found that, although the DLD-E3 residual activity in the muscle homogenate was higher in the current mutation than in G229C, the multi-enzymatic complex activity in the current mutation was undetectable compared to the G229C with a higher residual activity.